Latest & greatest articles for etanercept

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on etanercept or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on etanercept and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for etanercept

61. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195) Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor | Guidance and guidelines | NICE Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor Technology appraisal guidance [TA195 (...) ] Published date: 25 August 2010 Share Guidance on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they haven’t worked well enough. The recommendations also apply to biosimilar products of these technologies that have a marketing authorisation allowing the use of the biosimilar for the same

National Institute for Health and Clinical Excellence - Technology Appraisals2010

62. Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure

Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure Merkesdal S, Kirchhoff T, Wolka D, Ladinek G, Kielhorn A, Rubbert-Roth A Record Status This is a critical abstract (...) to first-line etanercept. The authors concluded that rituximab was cost-effective from the perspective of the health care payer, especially when considering productivity losses. The cost-effectiveness framework was conventional and methodologically sound and the authors’ conclusions appear to be valid. Type of economic evaluation Cost-utility analysis Study objective This study assessed the cost-effectiveness of rituximab compared with a second anti-tumour necrosis factor (TNF)-alpha treatment

NHS Economic Evaluation Database.2010

63. Etanercept (Enbrel®)

Etanercept (Enbrel®) Etanercept (Enbrel®) Etanercept (Enbrel®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Etanercept (Enbrel®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat (...) Assessment Report Advice No. 0210. 2010 Authors' conclusions Etanercept (Enbrel®) is not recommended for use within NHS Wales for the treatment of chronic severe plaque psoriasis in children and adolescents from the age of eight years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. The cost effectiveness data presented was insufficient for AWMSG to recommend the use of etanercept (Enbrel®) in NHS Wales. Final publication URL Indexing Status Subject

Health Technology Assessment (HTA) Database.2010

64. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. 20071701 2010 01 14 2010 01 25 2015 11 19 1533-4406 362 2 2010 Jan 14 The New England journal of medicine N. Engl. J. Med. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. 118-28 10.1056/NEJMoa0810652 Biologic agents offer a range of new therapeutic options for patients with psoriasis; however, the relative benefit-risk profiles of such therapies are not well known. We compared two biologic (...) agents, ustekinumab (an interleukin-12 and interleukin-23 blocker) and etanercept (an inhibitor of tumor necrosis factor alpha), for the treatment of psoriasis. We randomly assigned 903 patients with moderate-to-severe psoriasis to receive subcutaneous injections of either 45 or 90 mg of ustekinumab (at weeks 0 and 4) or high-dose etanercept (50 mg twice weekly for 12 weeks). The primary end point was the proportion of patients with at least 75% improvement in the psoriasis area-and-severity index

NEJM2010

65. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.

Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. 20124563 2010 02 03 2010 02 26 2015 11 19 1756-1833 340 2010 Feb 02 BMJ (Clinical research ed.) BMJ Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. c147 10.1136/bmj.c147 bmj.c147 To compare the efficacy over 12 weeks of two different etanercept regimens in treating (...) the skin manifestations of psoriasis in patients who also have psoriatic arthritis and to evaluate efficacy and safety over an additional 12 weeks of open label etanercept treatment. Design Randomised double blind multicentre outpatient study. 98 outpatient facilities in Europe, Latin America, and the Asia Pacific region. Participants 752 patients with both psoriasis (evaluated by dermatologists) and psoriatic arthritis (evaluated by rheumatologists). During the blinded portion of the study

BMJ2010

67. A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis

A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis Wiens A, Correr CJ, Pontarolo R, Venson R, Quinalha JV, Otuki MF CRD summary This review concluded that compared to controls, etanercept demonstrated greater (...) efficacy for management of rheumatoid arthritis, no difference in adverse events and fewer withdrawals due to lack of efficacy. Although the review process was well conducted, concerns with the analysis mean the results should be treated with some caution. Authors' objectives To evaluate the efficacy and safety of etanercept for treating rheumatoid arthritis. Searching MEDLINE, EMBASE, The Cochrane Library, SCIELO, LILACS and International Pharmaceutical Abstracts were searched without language or date

DARE.2009

68. A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy

A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy Colombo GL, Di Matteo S, Peris K, Fargnoli MC, Esposito M, Mazzotta A, Chimenti S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of etanercept versus non-systemic therapy, for chronic moderate-to-severe plaque psoriasis, in adults who failed to respond to, had a contraindication to, or were intolerant to other systemic therapies. The authors concluded that etanercept was cost-effective, especially

NHS Economic Evaluation Database.2009

69. Economic evaluation of etanercept in the management of chronic plaque psoriasis

Economic evaluation of etanercept in the management of chronic plaque psoriasis Economic evaluation of etanercept in the management of chronic plaque psoriasis Economic evaluation of etanercept in the management of chronic plaque psoriasis Lloyd A, Reeves P, Conway P, Reynolds A, Baxter G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of etanercept 50mg twice weekly in adults with moderate to severe plaque psoriasis, who were unable to take standard systemic therapies. The authors concluded that etanercept 50mg was cost-effective from the perspective of the UK National Health Service, especially in patients with severe disease or poor quality of life at baseline. The study was well conducted

NHS Economic Evaluation Database.2009

70. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials

Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled (...) trials Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ CRD summary This review concluded that while there was no statistically significant difference in malignancy risk between patients with rheumatoid arthritis treated with etanercept and those treated with control interventions, a clinically meaningful association could not be excluded. This conclusion reflected the results of the review and is likely to be reliable. Authors' objectives To assess the risk of malignancy associated

DARE.2009

71. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week

Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week 18576334 2008 07 15 2008 08 08 2015 11 19 0004-3591 58 7 2008 Jul Arthritis and rheumatism Arthritis Rheum. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study (...) . 1921-30 10.1002/art.23493 To evaluate the efficacy and safety of treatment with 50 mg of etanercept twice a week plus weekly methotrexate (MTX; > or =15 mg) in patients with rheumatoid arthritis (RA) who had a suboptimal response to 50 mg of etanercept once a week plus weekly MTX (> or =15 mg). In this multicenter, randomized, double-blind, active drug-controlled study, suboptimal responders to treatment with MTX plus etanercept 50 mg once weekly were given MTX plus etanercept 50 mg twice weekly (n

EvidenceUpdates2008

72. Adalimumab, etanercept and infliximab for ankylosing spondylitis (TA143)

Adalimumab, etanercept and infliximab for ankylosing spondylitis (TA143) Adalimumab, etanercept and infliximab for ankylosing spondylitis | Guidance and guidelines | NICE Adalimumab, etanercept and infliximab for ankylosing spondylitis Technology appraisal guidance [TA143] Published date: 28 May 2008 Guidance . Explore Guidance app Copyright © 2017 National Institute for Health and Care Excellence. All rights reserved.

National Institute for Health and Clinical Excellence - Technology Appraisals2008

73. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials

Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled (...) trials Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A CRD summary This review assessed the efficacy and safety of alefacept, efalizumab, etanercept and infliximab for treatment of moderate to severe plaque psoriasis and concluded that all treatments yielded significant improvements over placebo in the short term with an increased risk of adverse events. The authors’ conclusions from this generally well-conducted review reflected the evidence and are likely to be reliable. Authors

DARE.2008

74. Etanercept treatment for children and adolescents with plaque psoriasis.

Etanercept treatment for children and adolescents with plaque psoriasis. 18199863 2008 01 17 2008 01 29 2015 11 19 1533-4406 358 3 2008 Jan 17 The New England journal of medicine N. Engl. J. Med. Etanercept treatment for children and adolescents with plaque psoriasis. 241-51 10.1056/NEJMoa066886 Etanercept, a soluble tumor necrosis factor receptor, has been shown to lessen disease severity in adult patients with psoriasis. We assessed the efficacy and safety of etanercept in children (...) and adolescents with moderate-to-severe plaque psoriasis. In this 48-week study, 211 patients with psoriasis (4 to 17 years of age) were initially randomly assigned to a double-blind trial of 12 once-weekly subcutaneous injections of placebo or 0.8 mg of etanercept per kilogram of body weight (to a maximum of 50 mg), followed by 24 weeks of once-weekly open-label etanercept. At week 36, 138 patients underwent a second randomization to placebo or etanercept to investigate the effects of withdrawal

NEJM2008

75. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. 18635256 2008 08 04 2008 08 13 2016 11 24 1474-547X 372 9636 2008 Aug 02 Lancet (London, England) Lancet Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind (...) , parallel treatment trial. 375-82 10.1016/S0140-6736(08)61000-4 Remission and radiographic non-progression are goals in the treatment of early rheumatoid arthritis. The aim of the combination of methotrexate and etanercept in active early rheumatoid arthritis (COMET) trial is to compare remission and radiographic non-progression in patients treated with methotrexate monotherapy or with methotrexate plus etanercept. 542 outpatients who were methotrexate-naive and had had early moderate-to-severe

Lancet2008

76. Adalimumab, etanercept, and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation

Adalimumab, etanercept, and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation Adalimumab, etanercept, and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please

NIHR HTA programme2007

77. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review

The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response (...) in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsoe B, Saxne T CRD summary This review compared tumour necrosis factor-alpha blocking drugs for rheumatoid arthritis and concluded that adalimumab, etanercept and infliximab had similar efficacy, but infliximab may need higher doses for a similar effect. Given that this was based on an indirect comparison of only one trial of each

DARE.2007

78. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (TA130)

Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (TA130) Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis | Guidance and guidelines | NICE Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis Technology appraisal guidance [TA130] Published date: 22 October 2007 Guidance . Explore Guidance app Copyright © 2017 National Institute for Health and Care Excellence. All rights reserved.

National Institute for Health and Clinical Excellence - Technology Appraisals2007

79. The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK

The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK Ara R M, Reynolds A V, Conway P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of long-term etanercept (ETN) treatment in patients with severe ankylosing spondylitis (AS). The authors concluded that ETN was a cost-effective treatment for AS in the UK, but more research into AS costs and utilities was needed. The methodology was generally satisfactory; however there were some limitations in the reporting

NHS Economic Evaluation Database.2007

80. The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis

The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis Bravo Vergel Y, Hawkins N S, Claxton K, Asseburg C, Palmer S, Woolacott N, Bruce I N, Sculpher M J Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study compared two tumour necrosis factor antagonists, etanercept and infliximab, with palliative care for the treatment of patients with psoriatic arthritis. The authors concluded that only etanercept was within the acceptable cost-effectiveness thresholds defined

NHS Economic Evaluation Database.2007